Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Publication/Presentation Date
11-2018
Volume
132
Issue
1
First Page
804
Last Page
804
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Fellows and Residents
Document Type
Article
COinS